Association between CD4 lymphocyte count and the incidence of comorbidities in Human immunodeficiency virus positive patients with virological suppression after antiretroviral treatment
Restricted accessResearch articleFirst published online October, 2024
Association between CD4 lymphocyte count and the incidence of comorbidities in Human immunodeficiency virus positive patients with virological suppression after antiretroviral treatment
The incidence of comorbidities is higher in HIV-positive patients than in the general population due to factors, such as HIV-related chronic inflammation. There is no consensus on whether a low CD4 lymphocyte count after virological suppression at long-term follow-up increases the risk of comorbidities. This study evaluates the association between CD4 lymphocyte count and the incidence of comorbidities during the first 5 years of virological suppression after highly active antiretroviral treatment.
Methods
We conducted a cohort study of HIV-positive adults who achieved virological suppression in an HIV program between 2002 and 2016 in Colombia. A generalized equation estimation model was used to estimate the association between CD4 lymphocyte count and the incidence of comorbidities.
Results
A follow-up period of at least 1 year was completed in 921 HIV-positive patients with virological suppression. We found 71 comorbidities during a maximum of 5 years of follow-up; 41 (59%) were AIDS-defining comorbidities and 19 (46%) of them occurred during the first semester. Thirty cases of non-AIDS- defining comorbidities were diagnosed.
We did not find any association between CD4 lymphocyte count and the incidence of comorbidities (OR 0.92, CI 95% 0.45 -1.91 for CD4 201-499 cells/µL vs CD4 ≤200 cells/µL, and OR 0.55, 95% CI 0.21-1.44 for CD4 ≥500 cells/µL vs CD4 ≤200 cells/µL).
Conclusion
No association was found between CD4 lymphocyte count and the incidence of AIDS-defining or non-AIDS-defining comorbidities in patients with virological suppression. Further studies are needed to assess the risk of comorbidities in this population to design interventions aimed at improving their prognosis.
KilaruKRKumarASippyN, et al.Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Med2006; 7(2): 99–104.
AchhraACPetoumenosKLawMG. Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals. Curr Opin HIV AIDS2014; 9(1): 63–71.
6.
FeinsteinMJHsuePYBenjaminL, et al.Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American heart association. Circulation2019; 140(2): e98–124.
7.
LurainKYarchoanRRamaswamiR. The changing face of HIV-associated malignancies: advances, opportunities, and future directions. Am Soc Clin Oncol Educ Book2019; 39: 36–40.
8.
ZoufalyACozzi-LepriAReekieJ, et al.Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS One2014; 9(1): e87160.
9.
AlthoffKNGeboKAMooreRD, et al.Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV2019; 6(2): e93–104.
10.
De BoniRVelosoVGGrinsztejnB. Epidemiology of HIV in Latin America and the caribbean. Curr Opin HIV AIDS2014; 9(2): 192–198.
11.
RasmussenLDEngsigFNChristensenH, et al.Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS2011; 25(13): 1637–1646.
12.
BockPNelKFattiG, et al.Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa. HIV Med2019; 20(6): 392–403.
13.
LapadulaGChatenoudLGoriA, et al.Risk of severe non AIDS events is increased among patients unable to increase their CD4+ T-cell counts >200+/μl despite effective HAART. PLoS One2015; 10(5): e0124741.
14.
FreibergMSChangCCHKullerLH, et al.HIV infection and the risk of acute myocardial infarction. JAMA Intern Med2013; 173(8): 614–622.
15.
SidhuVKFoisyMMHughesCA. Discontinuing pneumocystis jirovecii pneumonia prophylaxis in HIV-infected patients with a CD4 cell count <200 cells/mm3. Ann Pharmacother2015; 49(12): 1343–1348.
16.
TaiwoBLiXPalellaF, et al.Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART. HIV Med2009; 10(10): 657–660.
17.
Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoordYoungJPsichogiouM, et al.CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med2012; 9(3): e1001194.
18.
van LelyveldSFLGrasLKesselringA, et al.Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS Lond Engl2012; 26(4): 465–474.
19.
Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269(6):729–730.
20.
BritoRMNguyenDTJohnsonJR, et al.Chronic kidney disease in patients infected with human immunodeficiency virus (HIV) in an urban cohort. PLoS One2019; 14(4): e0215575.
21.
AyeleWMulugetaADestaA, et al.Treatment outcomes and their determinants in HIV patients on anti-retroviral treatment program in selected health facilities of kembata and hadiya zones, southern nations, nationalities and peoples region, Ethiopia. BMC Publ Health2015; 15: 826.
22.
MocroftAFurrerHJMiroJM, et al.The incidence of AIDS-defining illnesses at a current CD4 count ≥200 cells/µL in the post–combination antiretroviral therapy era. Clin Infect Dis2013; 57(7): 1038–1047.
23.
AchhraACAminJLawMG, et al.Immunodeficiency and the risk of serious clinical endpoints in a well-studied cohort of treated HIV-infected patients. AIDS Lond Engl2010; 24(12): 1877–1886.
24.
EkrikpoUEKengneAPBelloAK, et al.Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS One2018; 13(4): e0195443.
25.
GarciaFde LazzariEPlanaM, et al.Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr2004; 36(2): 702–713.
26.
Group TIES Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med2009; 361(16): 1548–1559.
HarrisRJSterneJACAbgrallS, et al.Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther2008; 13(8): 959–967.
29.
Castillo-RozasGShengxinTMendesP, et al.Clinical outcomes and risk factors for immune recovery and all-cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study. JIAS2024; 27: e26214.
30.
HawNLeskoCNgD, et al.Incidence of non-AIDS defining comorbidities among young adults with perinatally-acquired HIV in North America, 2000-2019. AIDS2024; 10: 1097.
31.
JantarapakdeJPhanuphakNChaturawitC, et al.Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. AIDS Patient Care STDS2014; 28(7): 331–340.
32.
MaTMaHAlA, et al.Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis2020; 73(11): e3572–e3605.
